

Sarah Onuora

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8524258/publications.pdf>

Version: 2024-02-01

168
papers

352
citations

1162367

8
h-index

1372195

10
g-index

173
all docs

173
docs citations

173
times ranked

758
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibit tankyrase to preserve OA cartilage?. Nature Reviews Rheumatology, 2020, 16, 3-3.	3.5	0
2	New autoinflammatory disease caused by non-cleavable RIPK1 variants. Nature Reviews Rheumatology, 2020, 16, 61-61.	3.5	0
3	First EULAR recommendations for Sjögren syndrome published. Nature Reviews Rheumatology, 2020, 16, 2-2.	3.5	2
4	Physical therapy better than steroids for knee OA. Nature Reviews Rheumatology, 2020, 16, 296-296.	3.5	0
5	Early referral matters for RA outcomes. Nature Reviews Rheumatology, 2020, 16, 350-350.	3.5	0
6	Hospitalization for infection on the rise in gout. Nature Reviews Rheumatology, 2020, 16, 296-296.	3.5	1
7	Targeting adenosine in SSc. Nature Reviews Rheumatology, 2020, 16, 298-298.	3.5	2
8	Tanezumab improves difficult-to-treat OA. Nature Reviews Rheumatology, 2020, 16, 296-296.	3.5	0
9	Anti-TNF response falls short in real-world cohort. Nature Reviews Rheumatology, 2020, 16, 350-350.	3.5	0
10	MMF comparable to cyclophosphamide in AAV. Nature Reviews Rheumatology, 2020, 16, 350-350.	3.5	0
11	Increased risk of infection-related death in SLE. Nature Reviews Rheumatology, 2020, 16, 350-350.	3.5	0
12	CCA relapse common in ustekinumab trial. Nature Reviews Rheumatology, 2020, 16, 296-296.	3.5	0
13	Synovial fibroblast expansion in RA is driven by Notch signalling. Nature Reviews Rheumatology, 2020, 16, 349-349.	3.5	4
14	IL-37 linked to gout pathogenesis and treatment. Nature Reviews Rheumatology, 2020, 16, 250-250.	3.5	5
15	Pro-senescence therapy reduces joint inflammation. Nature Reviews Rheumatology, 2020, 16, 249-249.	3.5	1
16	Plasma exchange fails to improve outcomes for ANCA-associated vasculitis. Nature Reviews Rheumatology, 2020, 16, 185-185.	3.5	0
17	Gene expression profiles in muscle differ in myositis subtypes. Nature Reviews Rheumatology, 2020, 16, 409-409.	3.5	0
18	New data emerging on outcomes for patients with COVID-19 and rheumatic diseases. Nature Reviews Rheumatology, 2020, 16, 407-407.	3.5	3

#	ARTICLE	IF	CITATIONS
19	Abatacept no better than placebo for pSS. <i>Nature Reviews Rheumatology</i> , 2020, 16, 186-186.	3.5	3
20	Leflunomide plus glucocorticoids for IgG4-RD. <i>Nature Reviews Rheumatology</i> , 2020, 16, 186-186.	3.5	0
21	ABCG2 SNP associated with early-onset gout. <i>Nature Reviews Rheumatology</i> , 2020, 16, 186-186.	3.5	3
22	Tofacitinib alleviates pain in RA, PsA and AS. <i>Nature Reviews Rheumatology</i> , 2020, 16, 186-186.	3.5	4
23	TYK2 inhibition halts SpA. <i>Nature Reviews Rheumatology</i> , 2020, 16, 248-248.	3.5	1
24	Positive results for anifrolumab in phase III SLE trial. <i>Nature Reviews Rheumatology</i> , 2020, 16, 125-125.	3.5	4
25	EULAR updates its RA management recommendations. <i>Nature Reviews Rheumatology</i> , 2020, 16, 128-128.	3.5	1
26	Gene therapy counteracts bone loss in osteoporosis. <i>Nature Reviews Rheumatology</i> , 2019, 15, 513-513.	3.5	8
27	<i>P. gingivalis</i> exacerbates arthritis via gut barrier dysfunction. <i>Nature Reviews Rheumatology</i> , 2019, 15, 512-512.	3.5	1
28	Neuronal Fc γ 3 receptors mediate joint pain in arthritis. <i>Nature Reviews Rheumatology</i> , 2019, 15, 450-450.	3.5	1
29	Stratifying Sjögren syndrome into symptom-based subgroups. <i>Nature Reviews Rheumatology</i> , 2019, 15, 698-698.	3.5	1
30	Targeting the CRP α -HIF1 β axis in RA improves response to leflunomide. <i>Nature Reviews Rheumatology</i> , 2019, 15, 699-699.	3.5	0
31	Vaccination guidance updated. <i>Nature Reviews Rheumatology</i> , 2019, 15, 574-574.	3.5	0
32	Is Kawasaki disease a form of IgA vasculitis?. <i>Nature Reviews Rheumatology</i> , 2019, 15, 636-636.	3.5	1
33	Improving how we talk about gout. <i>Nature Reviews Rheumatology</i> , 2019, 15, 635-635.	3.5	0
34	A new model to study BAFF-independent SLE. <i>Nature Reviews Rheumatology</i> , 2019, 15, 636-636.	3.5	0
35	Complement activation precedes classifiable SLE. <i>Nature Reviews Rheumatology</i> , 2019, 15, 636-636.	3.5	0
36	Taking ABAT to OA. <i>Nature Reviews Rheumatology</i> , 2019, 15, 700-700.	3.5	0

#	ARTICLE	IF	CITATIONS
37	LLDAS is an attainable SLE treatment target. <i>Nature Reviews Rheumatology</i> , 2019, 15, 636-636.	3.5	0
38	Novel cytokine, IL-41, linked with PsA. <i>Nature Reviews Rheumatology</i> , 2019, 15, 636-636.	3.5	4
39	New insights into myositis genetics. <i>Nature Reviews Rheumatology</i> , 2019, 15, 451-451.	3.5	0
40	Rare variants in SLE risk genes drive disease. <i>Nature Reviews Rheumatology</i> , 2019, 15, 384-384.	3.5	1
41	IL-36 inhibition to treat OA. <i>Nature Reviews Rheumatology</i> , 2019, 15, 386-386.	3.5	3
42	Engineered fusion protein disrupts CD40 signalling. <i>Nature Reviews Rheumatology</i> , 2019, 15, 385-385.	3.5	0
43	Daily atorvastatin safe for patients with RA. <i>Nature Reviews Rheumatology</i> , 2019, 15, 318-318.	3.5	0
44	TIGIT-Ig shows therapeutic potential in SLE. <i>Nature Reviews Rheumatology</i> , 2019, 15, 318-318.	3.5	0
45	Namulumab improves RA symptoms. <i>Nature Reviews Rheumatology</i> , 2019, 15, 318-318.	3.5	2
46	Burden of musculoskeletal diseases increasing. <i>Nature Reviews Rheumatology</i> , 2019, 15, 318-318.	3.5	2
47	Hyperactive macrophages link heart and joint disease. <i>Nature Reviews Rheumatology</i> , 2018, 14, 182-182.	3.5	0
48	RA synovium harbours distinct fibroblast subsets. <i>Nature Reviews Rheumatology</i> , 2018, 14, 250-250.	3.5	1
49	Bystander-activated T cells contribute to Lyme arthritis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 123-123.	3.5	1
50	T cells in blood mark Sjögren syndrome activity. <i>Nature Reviews Rheumatology</i> , 2018, 14, 122-122.	3.5	0
51	Methotrexate for chronic chikungunya arthritis?. <i>Nature Reviews Rheumatology</i> , 2018, 14, 122-122.	3.5	0
52	Long-term mavrilimumab safe and effective. <i>Nature Reviews Rheumatology</i> , 2018, 14, 122-122.	3.5	0
53	Effects of certolizumab pegol sustained at 4 years. <i>Nature Reviews Rheumatology</i> , 2018, 14, 122-122.	3.5	0
54	Potassium channel regulates osteoclastogenesis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 64-64.	3.5	1

#	ARTICLE	IF	CITATIONS
55	Anti-TNF kills the macrophage response. Nature Reviews Rheumatology, 2018, 14, 64-64.	3.5	7
56	Biologics and risk of second malignant neoplasm. Nature Reviews Rheumatology, 2018, 14, 62-62.	3.5	2
57	Tofacitinib shows promise in PsA trials. Nature Reviews Rheumatology, 2018, 14, 4-4.	3.5	2
58	Higher disease risk in children of women with RA. Nature Reviews Rheumatology, 2018, 14, 62-62.	3.5	1
59	Rituximab improves SLE disease activity. Nature Reviews Rheumatology, 2018, 14, 62-62.	3.5	1
60	TNF drives cryopyrinopathies in mice. Nature Reviews Rheumatology, 2018, 14, 63-63.	3.5	1
61	Hydroxychloroquine no HERO for hand OA. Nature Reviews Rheumatology, 2018, 14, 248-248.	3.5	0
62	New insights into risk factors for GPA. Nature Reviews Rheumatology, 2018, 14, 248-248.	3.5	1
63	Incidence of flare is increased in pregnancy. Nature Reviews Rheumatology, 2018, 14, 248-248.	3.5	0
64	Subtype of JIA is genetically similar to adult RA. Nature Reviews Rheumatology, 2018, 14, 181-181.	3.5	2
65	Anti-NXP2 antibodies associated with severe JDM. Nature Reviews Rheumatology, 2018, 14, 248-248.	3.5	4
66	Obesity hampers effects of anti-TNF agents. Nature Reviews Rheumatology, 2018, 14, 320-320.	3.5	0
67	Denosumab shows promise for GIOP. Nature Reviews Rheumatology, 2018, 14, 320-320.	3.5	0
68	Triple therapy boosts survival in catastrophic APS. Nature Reviews Rheumatology, 2018, 14, 320-320.	3.5	0
69	Flares not linked to ultrasound findings in JIA. Nature Reviews Rheumatology, 2018, 14, 320-320.	3.5	0
70	Systemic JIA genetically distinct. Nature Reviews Rheumatology, 2017, 13, 65-65.	3.5	0
71	Hit the DEK!. Nature Reviews Rheumatology, 2017, 13, 196-197.	3.5	0
72	Antifibrotic effects of PDE4 blockade?. Nature Reviews Rheumatology, 2017, 13, 198-198.	3.5	1

#	ARTICLE	IF	CITATIONS
73	Loss of immunoinhibitory checkpoint implicated in GCA. Nature Reviews Rheumatology, 2017, 13, 129-129.	3.5	2
74	IL-37 fights inflammation-induced fatigue. Nature Reviews Rheumatology, 2017, 13, 258-258.	3.5	0
75	UCMA links cartilage and bone in OA. Nature Reviews Rheumatology, 2017, 13, 130-130.	3.5	7
76	Short telomeres in gout linked with flares and CVD. Nature Reviews Rheumatology, 2017, 13, 324-324.	3.5	1
77	Metabolic syndrome and risk of knee OA. Nature Reviews Rheumatology, 2017, 13, 257-257.	3.5	2
78	Celecoxib reduces risk of ulcer bleeding. Nature Reviews Rheumatology, 2017, 13, 324-324.	3.5	3
79	Obesity skews markers of inflammation. Nature Reviews Rheumatology, 2017, 13, 323-323.	3.5	3
80	Hippo signalling influences T cell fate. Nature Reviews Rheumatology, 2017, 13, 389-389.	3.5	6
81	Anakinra effective for resistant FMF in RCT. Nature Reviews Rheumatology, 2017, 13, 2-2.	3.5	2
82	Anti-TNF agents go head-to-head. Nature Reviews Rheumatology, 2017, 13, 2-2.	3.5	3
83	Sarilumab more effective than adalimumab. Nature Reviews Rheumatology, 2017, 13, 2-2.	3.5	6
84	Human gut bacteria induce TH17 cells. Nature Reviews Rheumatology, 2017, 13, 2-2.	3.5	4
85	Multi-pronged approach uncovers sJIA mechanisms. Nature Reviews Rheumatology, 2017, 13, 631-631.	3.5	0
86	Wnt inhibitor shows potential as a DMOAD. Nature Reviews Rheumatology, 2017, 13, 634-634.	3.5	11
87	Evidence of gut-driven inflammation in new JIA. Nature Reviews Rheumatology, 2017, 13, 632-632.	3.5	1
88	Cytokines alter inflammatory responses via chromatin changes. Nature Reviews Rheumatology, 2017, 13, 569-569.	3.5	1
89	Infection risk after switching biologics. Nature Reviews Rheumatology, 2017, 13, 570-570.	3.5	0
90	Reinforcing 'treat to target' for SpA. Nature Reviews Rheumatology, 2017, 13, 514-514.	3.5	0

#	ARTICLE	IF	CITATIONS
91	Ultrasonography in GCA assessment. <i>Nature Reviews Rheumatology</i> , 2017, 13, 695-695.	3.5	0
92	JAK-ing up inadequate RA therapy. <i>Nature Reviews Rheumatology</i> , 2017, 13, 513-513.	3.5	1
93	MIF drives inflammation and bone formation in AS. <i>Nature Reviews Rheumatology</i> , 2017, 13, 451-451.	3.5	4
94	Caution needed in use of gabapentinoids for LBP. <i>Nature Reviews Rheumatology</i> , 2017, 13, 570-570.	3.5	0
95	Intravenous golimumab effective for PsA. <i>Nature Reviews Rheumatology</i> , 2017, 13, 570-570.	3.5	0
96	Molecular imaging detects activated macrophages. <i>Nature Reviews Rheumatology</i> , 2016, 12, 313-313.	3.5	11
97	IFN γ signals control germinal centre formation. <i>Nature Reviews Rheumatology</i> , 2016, 12, 312-312.	3.5	5
98	Autoantibodies to PDGFR are profibrotic in vivo. <i>Nature Reviews Rheumatology</i> , 2016, 12, 316-316.	3.5	1
99	Stroke risk increased after herpes zoster infection. <i>Nature Reviews Rheumatology</i> , 2016, 12, 622-622.	3.5	1
100	Epratuzumab not effective in phase III trials. <i>Nature Reviews Rheumatology</i> , 2016, 12, 622-622.	3.5	4
101	Local versus systemic treatment for tenosynovitis. <i>Nature Reviews Rheumatology</i> , 2016, 12, 622-622.	3.5	0
102	Joint resurfacing possibilities loom large. <i>Nature Reviews Rheumatology</i> , 2016, 12, 497-497.	3.5	0
103	Apoptotic cells induce immune memory. <i>Nature Reviews Rheumatology</i> , 2016, 12, 559-559.	3.5	3
104	DNASE1L3 prevents anti-DNA responses. <i>Nature Reviews Rheumatology</i> , 2016, 12, 437-437.	3.5	1
105	Vagus nerve stimulation reduces RA severity in patients. <i>Nature Reviews Rheumatology</i> , 2016, 12, 500-500.	3.5	13
106	A nose for cartilage repair. <i>Nature Reviews Rheumatology</i> , 2016, 12, 691-691.	3.5	1
107	Metabolic changes modify Treg cell function. <i>Nature Reviews Rheumatology</i> , 2016, 12, 621-621.	3.5	2
108	Adalimumab drives Treg cell expansion via membrane TNF. <i>Nature Reviews Rheumatology</i> , 2016, 12, 438-438.	3.5	3

#	ARTICLE	IF	CITATIONS
109	Muscle pathology helps predict JDM outcomes. <i>Nature Reviews Rheumatology</i> , 2016, 12, 375-375.	3.5	0
110	Neutrophil microvesicles protect cartilage in arthritis. <i>Nature Reviews Rheumatology</i> , 2016, 12, 1-1.	3.5	1
111	Genetic variation affects IL-6 response in synovial fibroblasts. <i>Nature Reviews Rheumatology</i> , 2016, 12, 2-2.	3.5	5
112	Cell-type-specific approach to TNF inhibition. <i>Nature Reviews Rheumatology</i> , 2016, 12, 194-194.	3.5	3
113	Could glucose metabolism be a sweet target for RA therapy?. <i>Nature Reviews Rheumatology</i> , 2016, 12, 131-131.	3.5	10
114	TFH cells link gut microbiota and arthritis. <i>Nature Reviews Rheumatology</i> , 2016, 12, 133-133.	3.5	3
115	An evolving autoantibody response in RA?. <i>Nature Reviews Rheumatology</i> , 2016, 12, 193-193.	3.5	0
116	Chondrocyte clock maintains cartilage tissue. <i>Nature Reviews Rheumatology</i> , 2016, 12, 71-71.	3.5	6
117	Clues to the HLA-RA connection from T-cell crossreactivity to vinculin and microorganisms. <i>Nature Reviews Rheumatology</i> , 2015, 11, 384-384.	3.5	3
118	BiP peptides induce epitope-specific T-cell reactions in RA. <i>Nature Reviews Rheumatology</i> , 2015, 11, 259-259.	3.5	1
119	Targeting myostatin could prevent bone destruction in inflammatory arthritis. <i>Nature Reviews Rheumatology</i> , 2015, 11, 504-504.	3.5	8
120	Adipocyte-myofibroblast transition: linking intradermal fat loss to skin fibrosis in SSc. <i>Nature Reviews Rheumatology</i> , 2015, 11, 63-63.	3.5	8
121	Glucosamine-chondroitin combo improves knee OA pain. <i>Nature Reviews Rheumatology</i> , 2015, 11, 126-126.	3.5	1
122	Potent small molecule extinguishes the NLRP3 inflammasome. <i>Nature Reviews Rheumatology</i> , 2015, 11, 198-198.	3.5	3
123	Demethylation of IFN-regulated genes in SLE neutrophils. <i>Nature Reviews Rheumatology</i> , 2015, 11, 128-128.	3.5	1
124	Manipulating the FLS 'proteoglycan switch' could offer a new approach to RA therapy. <i>Nature Reviews Rheumatology</i> , 2015, 11, 381-381.	3.5	0
125	IgG immune complexes directly regulate bone homeostasis. <i>Nature Reviews Rheumatology</i> , 2015, 11, 257-257.	3.5	3
126	Targeting epigenetic regulation of osteoclastogenesis to prevent bone loss. <i>Nature Reviews Rheumatology</i> , 2015, 11, 195-195.	3.5	1

#	ARTICLE	IF	CITATIONS
127	Going upstream: peptidomimetics block shared-epitope signalling. <i>Nature Reviews Rheumatology</i> , 2015, 11, 320-320.	3.5	1
128	PR3 on apoptotic cells promotes inflammation in GPA. <i>Nature Reviews Rheumatology</i> , 2015, 11, 683-683.	3.5	3
129	Blood vessel microenvironment sustains cell renewal in Dupuytren contracture nodules. <i>Nature Reviews Rheumatology</i> , 2015, 11, 444-444.	3.5	1
130	C5orf30 regulates severity of tissue destruction in RA. <i>Nature Reviews Rheumatology</i> , 2015, 11, 622-622.	3.5	3
131	Cartilage matrix stiffness regulates chondrocyte metabolism and OA pathogenesis. <i>Nature Reviews Rheumatology</i> , 2015, 11, 504-504.	3.5	13
132	PBMCs stimulate chondrocyte migration and cartilage repair. <i>Nature Reviews Rheumatology</i> , 2015, 11, 563-563.	3.5	8
133	Meta-analysis reveals novel overlap in genetic aetiologies of paediatric autoimmune disorders. <i>Nature Reviews Rheumatology</i> , 2015, 11, 561-561.	3.5	0
134	Novel NF κ B inhibitor associated with RA severity. <i>Nature Reviews Rheumatology</i> , 2015, 11, 684-684.	3.5	4
135	Can tofacitinib be used as first-line monotherapy for RA?. <i>Nature Reviews Rheumatology</i> , 2014, 10, 443-443.	3.5	4
136	A new therapeutic approach for APS?. <i>Nature Reviews Rheumatology</i> , 2014, 10, 259-259.	3.5	0
137	A new STING-associated monogenic autoinflammatory disease. <i>Nature Reviews Rheumatology</i> , 2014, 10, 512-512.	3.5	3
138	Does metal-on-metal hip resurfacing confer a survival advantage over total hip replacement?. <i>Nature Reviews Rheumatology</i> , 2014, 10, 65-65.	3.5	0
139	Does norepinephrine influence cartilage repair?. <i>Nature Reviews Rheumatology</i> , 2014, 10, 383-383.	3.5	0
140	Ustekinumab after anti-TNF failure: a step closer to the PSUMMIT of psoriatic arthritis therapy?. <i>Nature Reviews Rheumatology</i> , 2014, 10, 125-125.	3.5	2
141	Immune surveillance stops joint-invading <i>Borrelia</i> in mice. <i>Nature Reviews Rheumatology</i> , 2014, 10, 638-638.	3.5	0
142	Dishing up functional human cartilage. <i>Nature Reviews Rheumatology</i> , 2014, 10, 321-321.	3.5	3
143	Methotrexate and bridging glucocorticoids in early RA. <i>Nature Reviews Rheumatology</i> , 2014, 10, 698-698.	3.5	1
144	Blood coagulation factor drives arthritis pathogenesis. <i>Nature Reviews Rheumatology</i> , 2014, 10, 700-700.	3.5	4

#	ARTICLE	IF	CITATIONS
145	A role for CXCR2 signalling in cartilage homeostasis. Nature Reviews Rheumatology, 2014, 10, 576-576.	3.5	2
146	Antibody against CSF-1 receptor protects bone and cartilage. Nature Reviews Rheumatology, 2014, 10, 260-260.	3.5	4
147	Epstein-Barr virus in Sjögren's syndrome salivary glands drives local autoimmunity. Nature Reviews Rheumatology, 2014, 10, 384-384.	3.5	4
148	Sprifermin shows cartilage-protective effects in knee OA. Nature Reviews Rheumatology, 2014, 10, 322-322.	3.5	7
149	Depleting plasmacytoid dendritic cells: a new therapeutic approach in SLE?. Nature Reviews Rheumatology, 2014, 10, 573-573.	3.5	0
150	A NET of peril for endothelial cells in SLE?. Nature Reviews Rheumatology, 2014, 10, 195-195.	3.5	1
151	Inflammasome-driven arthritis: a new model of RA?. Nature Reviews Rheumatology, 2014, 10, 445-445.	3.5	2
152	Targeting Rac1 via microparticle-based drug delivery system protects OA cartilage in vivo. Nature Reviews Rheumatology, 2014, 10, 1-1.	3.5	8
153	SSAT1 inhibition slows synovial fibroblast invasion. Nature Reviews Rheumatology, 2014, 10, 259-259.	3.5	3
154	A new path to treating arthritis?. Nature Reviews Rheumatology, 2013, 9, 2-2.	3.5	0
155	New insights into functional effects of the shared epitope. Nature Reviews Rheumatology, 2013, 9, 3-3.	3.5	0
156	OA chondrocytes made senescent by genomic DNA damage. Nature Reviews Rheumatology, 2012, 8, 502-502.	3.5	1
157	Spirochaete remnants could explain antibiotic-refractory Lyme arthritis. Nature Reviews Rheumatology, 2012, 8, 440-440.	3.5	0
158	Canakinumab relieves gout flares when treatment options are limited. Nature Reviews Rheumatology, 2012, 8, 369-369.	3.5	3
159	Evidence from animal studies supports the 'enthesal stress' hypothesis of ankylosing spondylitis. Nature Reviews Rheumatology, 2012, 8, 248-248.	3.5	1
160	Bare bones of glucocorticoid effects on metabolism. Nature Reviews Rheumatology, 2012, 8, 694-694.	3.5	0
161	RF levels predict RA risk in the general population. Nature Reviews Rheumatology, 2012, 8, 562-562.	3.5	5
162	Surgical options for hip OA: digging beneath the surface of implant survival. Nature Reviews Rheumatology, 2012, 8, 631-631.	3.5	1

#	ARTICLE	IF	CITATIONS
163	How bad is obesity for RA?. Nature Reviews Rheumatology, 2012, 8, 306-306.	3.5	4
164	GO-FURTHER with intravenous golimumab for active RA. Nature Reviews Rheumatology, 2012, 8, 439-439.	3.5	0
165	Does ultrasonography reliably detect bone erosion in RA metacarpophalangeal joints?. Nature Reviews Rheumatology, 2012, 8, 367-367.	3.5	0
166	Granulocyte-macrophage colony-stimulating factor required for inflammatory and arthritic pain. Nature Reviews Rheumatology, 2012, 8, 499-499.	3.5	3
167	Autophagy is central to joint destruction in arthritis. Nature Reviews Rheumatology, 2012, 8, 633-633.	3.5	4
168	JAK inhibition with tofacitinib curbs RANKL-induced joint damage. Nature Reviews Rheumatology, 2012, 8, 564-564.	3.5	3